Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Want to see JAZZ full AI Analyst Report?
JAZZ Stock Chart & Stats
$203.42
-$1.17(-0.95%)
At close: 4:00 PM EST
$203.42
-$1.17(-0.95%)
Day’s Range― - ―
52-Week Range$105.00 - $243.32
Previous CloseN/A
Volume75.28K
Average Volume (3M)945.68K
Market Cap
$14.49B
Enterprise Value$18.41B
Total Cash (Recent Filing)$2.87B
Total Debt (Recent Filing)$5.42B
Price to Earnings (P/E)503.8
Beta0.73
Next Earnings
Aug 05, 2026EPS Estimate
6.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding62,742,820
10 Day Avg. Volume927,024
30 Day Avg. Volume945,677
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio7.99
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue4.15
Enterprise Value/Gross Profit4.93
Enterprise Value/Ebitda46.56
Forecast
1Y Price Target
$261.82Price Target Upside28.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)25.21
Revenue Forecast (FY)$4.50B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent, large operating and free cash flow provides durable financial flexibility for R&D, commercialization, and debt servicing. Over a 2–6 month horizon this supports continued pipeline funding, commercialization of new launches, and optionality for M&A or buybacks despite volatile reported earnings.
Oncology Momentum & New LaunchesRapid oncology growth and early uptake of Midevo and ZYHERA diversify revenue away from concentration in sleep drugs. Sustainable oncology expansion reduces single-product risk, supports revenue resilience, and creates a multi-year commercial runway if trial and regulatory milestones continue to succeed.
High Gross MarginsVery high gross margins reflect pricing power and low cost-of-goods for specialty therapies, converting sales into substantial cash. This margin structure underpins long-term free cash flow generation and buffers R&D and commercial spend even when net income is episodically weak.
Bears Say
Elevated Absolute DebtDespite improved leverage metrics, a ~$5.4B absolute debt load constrains strategic flexibility and increases sensitivity to earnings volatility. Over the medium term this limits free capital for acquisitions or aggressive share returns and raises refinancing and interest-rate exposure risk.
Earnings VolatilityWide swings in net income and a very low TTM net margin (~0.7%) impair predictability of retained earnings and cash available after investment. For capital allocation and credit metrics, this volatility increases risk of covenant pressure and complicates long-term planning despite strong top-line and gross margins.
Structural Sleep‑Market CompetitionAnticipated generic oxybate volume and new wake‑promoter entrants threaten durable revenue and margin for the sleep franchise. Over months this can permanently reduce pricing power, increase marketing and access costs, and force greater reliance on oncology and new launches to sustain growth.
Jazz Pharmaceuticals News
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $105.00 and its highest was $243.32 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $14.49B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Aug 05, 2026 which is in 61 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on May 05, 2026. The company reported $6.34 earnings per share for the quarter, beating the consensus estimate of $4.641 by $1.699.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 6.19.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 62,742,820 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.34 in its last earnings report, beating expectations of $4.641. Following the earnings report the stock price went up 7.684%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$261.82 (28.71% Upside)
$261.82 (28.71% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 150.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Bullish
Bullish news 79%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.33%
12-Months-Change
Fundamentals
Return on Equity
0.71%
Trailing 12-Months
Asset Growth
2.82%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ Company Deck
JAZZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and substantial pipeline/regulatory progress that drove record Q1 revenue, robust product-level growth (notably oncology, Xywav and Epidiolex), solid cash generation and clear near-term catalysts (zanidatumab PDUFA, multiple interim readouts). Headline growth was partially boosted by an extra shipping week and FX effects, and management highlighted expected competitive dynamics in sleep and areas of margin and policy uncertainty. Overall, the positives (record revenue, high growth rates, cash strength, promising pivotal data and imminent regulatory milestones) outweigh the outlined risks and uncertainties.View all JAZZ earnings summariesJAZZ Stock 12 Month Forecast
Average Price Target
$261.82
▲(28.71% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Bio-Techne
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
3.58% Insiders
29.90% Mutual Funds
31.55% Other Institutional Investors
11.76% Public Companies and Individual Investors